Capecitabine in combination with radiotherapy for treatment of brain metastases in patients with breast cancer

Ekaterina A. Moskvina , V. A Gorbunova , D. R Naskhletashvili , S. V Medvedev , A. Kh Bekyashev , D. M Belov

Russian Journal of Oncology ›› 2015, Vol. 20 ›› Issue (1) : 13 -17.

PDF
Russian Journal of Oncology ›› 2015, Vol. 20 ›› Issue (1) : 13 -17. DOI: 10.17816/onco40099
Articles
research-article

Capecitabine in combination with radiotherapy for treatment of brain metastases in patients with breast cancer

Author information +
History +
PDF

Abstract

The article reviews the experience of capecitabine application in 65 breast cancer (BC) patients with metastatic brain damage. 35 patients underwent early chemoradiation, (brain irradiation) simultaneously with the start of capecitabine. In 30 patients delayed chemoradiation was conducted, in the first phase - induction chemotherapy with capecitabine, then brain irradiation in patients receiving capecitabine. The effectiveness of the immediate and long-term outcomes in the two groups was analyzed. In the group of early chemoradiotherapy objective effect in the brain was 77.2%. The median time to progression - 15.3 months. The median survival - 22 months. In the group of delayed chemoradiotherapy objective effect was 56.6%. The median time to progression - 12 months. The median life expectancy - 15.1 month. When comparing the time to disease progression in the brain in early chemoradiotherapy group (15.3 months), and the group of delayed chemoradiotherapy (12 months), and also when comparing the median survival in early groups (22 months) and delayed (15, 1 month.) chemoradiotherapy statistically significant differences were found (p = 0.3; p = 0.25, respectively). The reviewed modes of chemoradiotherapy with capecitabine (early and delayed chemoradiotherapy) had comparable effectiveness.

Keywords

brain metastases / breast cancer / capecitabine / radiation therapy

Cite this article

Download citation ▾
Ekaterina A. Moskvina, V. A Gorbunova, D. R Naskhletashvili, S. V Medvedev, A. Kh Bekyashev, D. M Belov. Capecitabine in combination with radiotherapy for treatment of brain metastases in patients with breast cancer. Russian Journal of Oncology, 2015, 20(1): 13-17 DOI:10.17816/onco40099

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2011; 22 [3 (85), прил. 1].

[2]

Burstein H.J., Lieberman G., Slamon D.J. et al. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann. Oncol. 2005; 16: 1772-7.

[3]

Chang E., Lob S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist. 2003; 8 (5): 398-410.

[4]

Siegelmann-Danieli N., Stein M., Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr. Med. Assoc. J. 2003; 5: 833-4.

[5]

Bendell J.C., Domchek S.M., Burstein H.J. et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003; 97: 2972-7.

[6]

De la Monte S.M., Hutchins G.M., Moore G.W. Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am. J. Med. 1984; 76: 11-7.

[7]

Samaan N.A., Buzdar A.U., Aldinger K.A. et al. Estrogen receptor: A prognostic factor in breast cancer. Cancer. 1981; 47: 554-60.

[8]

Tsao M.N., Lloyd N., Wong R. et al. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst. Rev. 2006; 3: CD003869.

[9]

Насхлеташвили Д.Р, Чмутин Г.Е., Карахан В.Б., Алешин В.А., Фу Р.Г., Москвина Е.А. и др. Опыт лечения капецитабином и трастузумабом метастатического поражения головного мозга при раке молочной железы с гиперэкспрессией Her-2/neu. Современная онкология. 2010; 12 (1): 13-4.

[10]

Naskhletashvili D.R., Gorbounova V.A., Bychkov M.B., Moskvina E.A., Markovich A.A., Chmutin G.E., Karahan V.B., Aloshin V.A. Capecitabine-based therapy for patients with brain metastases from breast cancer. Ann. Oncol.2010; 21 (suppl. 8): viii118 (354).

[11]

Насхлеташвили Д.Р, Бекяшев А.Х., Карахан В.Б., Москвина Е.А. Капецитабин в лечении больных раком молочной железы с метастазами в головном мозге. В кн.: Тезисы I Конференции “Юбщества специалистов онкологов по опухолям репродуктивной системы“ 31 вкт.-1 нояб 2011 г. Москва, РОНЦ. М.; 2011.

[12]

Москвина Е.А., Горбунова В.А., Насхлеташвили Д.Р., Бекяшев А.Х., Медведев С.В., Петерсон С.Б. Капецитабин в лечении метастатического поражения головного мозга у больных раком молочной железы. Опухоли головы и шеи. 2012; 3: 59-62.

[13]

Насхлеташвили Д.Р, Горбунова В.А., Москвина Е.А. Химиотерапия больных раком молочной железы с метастатическим поражением головного мозга. В кн.: Актуальные аспекты клинической маммологии / Под ред. Е.Б. Камповой-Полевой, С.М. Портного. М.: Авторская Академия; 2014: 457-63.

RIGHTS & PERMISSIONS

Eco-Vector

AI Summary AI Mindmap
PDF

155

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/